These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 35212154

  • 1. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F, Gao F, Wu H, Lu J, Xu Y, Zhao Y.
    Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
    [Abstract] [Full Text] [Related]

  • 2. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 3. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C, Barua S, Hsiao SJ, Mansukhani M, Saqi A, Murty V, Fernandes H.
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF, Wang WX, Xu CW, Huang LC, Li XF, Lan G, Zhai ZQ, Zhu YC, Du KQ, Lei L, Fang MY.
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [Abstract] [Full Text] [Related]

  • 6. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 7. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 8. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L.
    Lung Cancer; 2019 Nov 07; 137():19-22. PubMed ID: 31521978
    [Abstract] [Full Text] [Related]

  • 9. A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report.
    Wang C, Chen S, He Q, Sun T, Xu P.
    Invest New Drugs; 2022 Dec 07; 40(6):1350-1353. PubMed ID: 35666357
    [Abstract] [Full Text] [Related]

  • 10. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
    Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J.
    Sci Rep; 2017 Oct 02; 7(1):12510. PubMed ID: 28970558
    [Abstract] [Full Text] [Related]

  • 11. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G, Pajor G, Szuhai K, Morreau H, Kocsmár I, Kocsmár É, Pajor L, Kajtár B, Sárosi V, Lotz G, Tornóczky T.
    Lung Cancer; 2020 May 02; 143():80-85. PubMed ID: 32272316
    [Abstract] [Full Text] [Related]

  • 12. A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.
    Dai S, Liu XQ, Wu Q, Du CM, Liu Q, Xue YY, Luo F, Li Y.
    Lung Cancer; 2023 Jan 02; 175():121-124. PubMed ID: 36495785
    [Abstract] [Full Text] [Related]

  • 13. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
    Sui A, Song H, Li Y, Guo L, Wang K, Yuan M, Chen R.
    Medicine (Baltimore); 2021 Feb 26; 100(8):e24917. PubMed ID: 33663128
    [Abstract] [Full Text] [Related]

  • 14. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 15. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H, Liu Y, Wang W, Tang Y, Tian P, Li W.
    Ann Palliat Med; 2021 Jul 08; 10(7):8352-8357. PubMed ID: 33832282
    [Abstract] [Full Text] [Related]

  • 16. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y, Zhang X, Jiang Q, Wang B, Wang Y, Junrong Y.
    Lung Cancer; 2020 Aug 08; 146():370-372. PubMed ID: 32527613
    [Abstract] [Full Text] [Related]

  • 17. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ.
    Oncologist; 2020 Aug 08; 25(8):702-711. PubMed ID: 32386255
    [Abstract] [Full Text] [Related]

  • 18. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
    Tao H, Liu Z, Mu J, Gai F, Huang Z, Shi L.
    Diagn Pathol; 2022 Feb 10; 17(1):27. PubMed ID: 35144623
    [Abstract] [Full Text] [Related]

  • 19. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J, Chen HJ, Zhang XC, Su J, Zhou Q, Tu HY, Wang Z, Wang BC, Zhong WZ, Yang XN, Chen ZH, Ding Y, Wu X, Wang M, Fu JG, Yang Z, Zhang X, Shao YW, Wu YL, Yang JJ.
    Thorac Cancer; 2018 Sep 10; 9(9):1093-1103. PubMed ID: 29978950
    [Abstract] [Full Text] [Related]

  • 20. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L, Hou F, Liu Y, Li W, Zhang H.
    J Natl Compr Canc Netw; 2021 Nov 11; 20(1):2-6. PubMed ID: 34763318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.